Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_assertion type Assertion NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_head.
- NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_assertion wasGeneratedBy ECO_0000203 NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_provenance.
- NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_assertion wasDerivedFrom befree-2016 NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_provenance.
- NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_assertion SIO_000772 23161302 NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_provenance.
- NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_assertion evidence source_evidence_literature NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_provenance.
- NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_assertion description "[The aim of this subanalysis of a multicenter clinical trial was to compare the efficacy and safety of 48 weeks of pegylated interferon alpha-2a (180 μg weekly) with or without adefovir (10 mg daily) in patients with chronic delta hepatitis-induced advanced liver disease and in those with non-advanced liver disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1029353.RA7Jbn8esZW8q6zOKUaV_uEqhnmMyaVX7z-Q-09L0OAiY130_provenance.